Global Relevance

1,5-anhydroglucitol—the biomarker identified by the GlycoMark® test—has been described in more than 600 scientific and medical publications. With citations in peer-reviewed journals and publications recognized by ADA and IDF, GlycoMark, Inc.’s Compendium of Evidence details its utility for the intermediate term monitoring of glycemic control in people with diabetes. To access the most recent Compendium of Evidence, click here. 
Global Resources

Toyota Tsusho America, Inc. (TAI) operates six divisions, including: metals, automotive; food and consumer products; global production parts and logistics; machinery and energy; and chemicals and electronics—of which GlycoMark, Inc. is a component. TAI is owned exclusively by Toyota Tsusho Corporation (“TTC”), a corporation conducting business with customers around the world through a global network spanning more than 90 countries and 970 group companies. 

The Toyota Tsusho group’s ideal is to “Be the Right ONE” for its customers, its employees and its future. GlycoMark, Inc. is a joint venture between TAI (New York, NY), TTC (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), which enables the company to bring exceptional resources to the discovery and commercialization of innovative biomarkers for diabetes.
Global Reach
Newly appointed marketing director Michael Christov (pictured on the right) is working with a team of marketing professionals to expand awareness and demand of GlycoMark® as a perfect complement to A1C. In addition to publishing this email newsletter, the team is working on developing innovative partnerships with laboratories and physician offices across a variety of communications channels.
Copyright© April, *|CURRENT_YEAR|* issue. *|LIST:COMPANY|*, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

GlycoMark.com